2.48
Atai Life Sciences N V stock is traded at $2.48, with a volume of 2.01M.
It is up +0.40% in the last 24 hours and up +68.71% over the past month.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
See More
Previous Close:
$2.47
Open:
$2.5
24h Volume:
2.01M
Relative Volume:
1.05
Market Cap:
$496.84M
Revenue:
$314.00K
Net Income/Loss:
$-40.23M
P/E Ratio:
-8.8571
EPS:
-0.28
Net Cash Flow:
$-84.71M
1W Performance:
+6.90%
1M Performance:
+68.71%
6M Performance:
+66.44%
1Y Performance:
+75.89%
Atai Life Sciences N V Stock (ATAI) Company Profile
Name
Atai Life Sciences N V
Sector
Industry
Phone
49 89 2153 9035
Address
WALLSTRASSE 16, BERLIN
Compare ATAI with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ATAI
Atai Life Sciences N V
|
2.48 | 464.78M | 314.00K | -40.23M | -84.71M | -0.28 |
![]()
ONC
Beone Medicines Ltd Adr
|
257.00 | 26.69B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
443.82 | 114.81B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.282 | 41.83M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
85.54 | 6.60B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
483.07 | 65.36B | 14.09B | 4.50B | 2.96B | 39.28 |
Atai Life Sciences N V Stock (ATAI) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Nov-18-24 | Reiterated | H.C. Wainwright | Buy |
Apr-03-24 | Upgrade | Maxim Group | Hold → Buy |
Nov-01-22 | Initiated | Loop Capital | Buy |
Nov-30-21 | Initiated | Maxim Group | Buy |
Nov-11-21 | Initiated | ROTH Capital | Buy |
Oct-18-21 | Initiated | H.C. Wainwright | Buy |
Sep-01-21 | Initiated | Jefferies | Buy |
Jul-13-21 | Initiated | Berenberg | Buy |
Jul-13-21 | Initiated | Canaccord Genuity | Buy |
Jul-13-21 | Initiated | Cantor Fitzgerald | Buy |
Jul-13-21 | Initiated | Citigroup | Buy |
Jul-13-21 | Initiated | Cowen | Outperform |
Jul-13-21 | Initiated | Credit Suisse | Outperform |
Jul-13-21 | Initiated | RBC Capital Mkts | Sector Perform |
Jul-08-21 | Initiated | Aegis Capital | Buy |
View All
Atai Life Sciences N V Stock (ATAI) Latest News
ATAI and Beckley Psytech Set to Merge in Strategic All-Share Dea - GuruFocus
Regeneron makes obesity push; Atai, Alto ink brain drug deals - Yahoo Finance
ATAI Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of Atai Life Sciences N.V. is Fair to Shareholders - Business Wire
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BPMC, STRM, ATAI, STR on Behalf of Shareholders - PR Newswire
H.C. Wainwright maintains buy rating on atai Life Sciences stock By Investing.com - Investing.com India
H.C. Wainwright maintains buy rating on atai Life Sciences stock - Investing.com
Atai Life Sciences Merges With Beckley Psytech In Major Shakeup - Finimize
atai Life Sciences and Beckley Psytech merging - Seeking Alpha
Atai Life Sciences, Beckley Psytech to Merge in All-Stock Transaction - marketscreener.com
Transcript : Atai Life Sciences N.V., Beckley Psytech LimitedM&A Call - marketscreener.com
Thiel-Backed Psychedelic Drugmaker Atai to Combine With Beckley - Bloomberg
ATAI and Beckley Psytech Plan Merger in Strategic All-Share Deal | ATAI Stock News - GuruFocus
atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies - Yahoo Finance
Beckley Psytech & atai Life Sciences to combine expertise in pivotal merger - Mugglehead Magazine
atai Life Sciences to Participate in Upcoming Investor Conferences - Yahoo
2 ‘Strong Buy’ Psychedelic Stocks To Scoop Up ASAP - Barchart.com
Ex-Gov't Foe Joins Trump, RFK Jr.'s HHS To Lead Psychedelics Policy: What It Means For Investors - Benzinga
atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know - Nasdaq
atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? - sharewise
Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? - Yahoo Finance
atai Life Sciences holds annual general meeting - Investing.com Australia
atai Life Sciences holds annual general meeting By Investing.com - Investing.com India
ATAI Life Sciences Approves Key Governance Changes - TipRanks
Phase 2a data for BPL-003 ‘encouraging’ for Atai Life Sciences, says Jefferies - Yahoo Finance
ATAI Life Sciences Sees Significant Rise in Borrow Rate | ATAI S - GuruFocus
ATAI Stock Poised for Growth After Positive Phase 2a Data on BPL - GuruFocus
ATAI Stock Poised for Growth After Positive Phase 2a Data on BPL-003 | ATAI Stock News - GuruFocus
ATAI Life Sciences (ATAI) Shows Encouraging Mid-Stage Trial Resu - GuruFocus
atai Life Sciences reports positive data from mid-stage depression trial - Seeking Alpha
ATAI Reiterates a 'Buy' Rating with a Price Target of $10 | ATAI Stock News - GuruFocus
Atai Life Sciences Reports Positive Phase 2a Results for Treatment-Resistant Depression Drug - marketscreener.com
ATAI Life Sciences Reports Promising Findings from Depression Study | ATAI Stock News - GuruFocus
atai reports positive phase 2a results for depression treatment By Investing.com - Investing.com UK
atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech’s Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression - Yahoo Finance
Psychedelic stocks up after FDA chief’s comments (ATAI:NASDAQ) - Seeking Alpha
How Do Things Look For ATAI Life Sciences N.V (NASDAQ: ATAI) In The Short-Term? - Stocksregister
Despite Lacking Profits Atai Life Sciences (NASDAQ:ATAI) Seems To Be On Top Of Its Debt - simplywall.st
ATAI Explores Psychedelic Solutions for Veterans' Mental Health - GuruFocus
ATAI Explores Psychedelic Solutions for Veterans' Mental Health | ATAI Stock News - GuruFocus
Atai Life Sciences: Progress in Psychedelic Mental Health Treatments - TipRanks
Will Atai Get A New Lease Of Life? - RTTNews
Atai Life Sciences Reports First Quarter 2025 Financial Results - marketscreener.com
ATAI Reports Significant First Quarter Revenue Growth | ATAI Sto - GuruFocus
ATAI Sees Financial Boost with Cash Reserves Rise | ATAI Stock N - GuruFocus
ATAI Reports Significant First Quarter Revenue Growth | ATAI Stock News - GuruFocus
atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates - The Manila Times
Certain Restricted stock units of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
Certain Options of Atai Life Sciences N.V. are subject to a Lock-Up Agreement Ending on 14-MAY-2025. - marketscreener.com
ATAI Begins Phase 2 Study for Social Anxiety Treatment | ATAI St - GuruFocus
Atai Life Sciences Announces First Patient Dosed In Phase 2 Study Of Emp-01 For The Treatment Of Social Anxiety Disorder - marketscreener.com
atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder - Yahoo
Atai Life Sciences N V Stock (ATAI) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):